Abstract: A catheter is disclosed for providing pressure measurements at a vascular lesion. The catheter includes an outer component having a side opening the providing transverse access to a lumen thereof and an inner component slidably disposed within the lumen. The inner component has a guidewire lumen with a proximal side port. When the inner component is longitudinally translated relative to the outer component, the side port of the inner component is accessible through the side opening of the outer component for providing transverse access to a guidewire. A first pressure sensor is disposed proximate of a distal end of the outer component and a second pressure sensor is disposed proximate of a distal end of the inner component, such that relative longitudinal translation between the inner and outer components permits a distance between the first and second pressure sensors to be varied.

Abstract: A selectively attachable and removable visual and tactile assessment tool or clip for use with a mobile device is provided. Clip is an elongate member forming a curvilinear shape having a magnifying lens at a distal end thereof. Clip has a transparent tubular member disposed between first and second openings through the body portion of the clip. Tubular member has varying internal diameters to simulate, for example, the constriction or stenosis of a patient's vessel lumen. Once clip is attached to mobile device and the magnifying lens is positioned over the camera of the mobile device, a catheter is inserted through tubular member. The magnifying lens enlarges the size of the catheter displayed on the screen of the mobile device.

Abstract: Embodiments hereof relate to methods and systems for determining a pressure gradient across a lesion of a vessel without requiring the use of a pharmacological hyperemic agent. A measurement system includes at least an injection catheter and a pressure-sensing instrument or guidewire slidingly disposed through the catheter, the pressure-sensing guidewire including at least one pressure sensor configured to obtain a pressure measurement for use in determining the pressure gradient across the lesion. The catheter is configured to deliver or inject a non-pharmacological fluid, such as saline or blood, across the lesion in order to increase a flow rate there-through, thereby simulating hyperemia without the use of a pharmacological hyperemic agent. Once an increased flow rate that simulates hyperemia is achieved, the pressure sensor of the pressure-sensing guidewire may be utilized to measure the pressure gradient across the lesion in order to assess the severity of the lesion.

Abstract: A delivery system for an implantable medical device includes a tool and a tethering member extending side-by-side within an inner shaft thereof; the tool extends within a first lumen, being in sliding engagement therein, and includes a distal end coupling feature that protrudes from a distal end of the inner shaft; and the tethering member has a first segment extending within a second lumen, and a second segment extending from the first segment and distally from the distal end of the inner shaft to an end of the tethering member, which is configured to engage with a holding member of the device, and with which the coupling feature of the tool is configured to couple. A retainer may be joined to another end of the tethering member that protrudes from a proximal port of the system.

Abstract: A method of facilitating health of a patient includes determining, based on patient information, a risk score. The patient information includes clinical information and at least one of psychosocial information, experiential information, relational information, preferential information, demographic information, barrier information, and compliance information. The method further includes identifying a number of risk factors that influence the risk score; determining a level of influence that each risk factor has on the risk score; and causing a display device to present a representation of the risk score.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: Very strong, complex, unforgettable passwords unique to each web site are created for a user's Web site authentication by altering all or part of the web site address using, in a preferred embodiment, a predetermined encoding dictionary with more a single code for each entry and unique to each user. The entries in this preferred embodiment are single characters including characters used for words, punctuation, symbols and numerals; each single entry character appears more than once in the dictionary. The codes are of various character lengths and can be comprised of the same characters used in the entries. In a Web site authentication embodiment as well as for embodiments not used for Web site authentication, including pass-protecting files, the string of characters altered by encoding can be a private word or group of words. In another embodiment the password created by encoding is pseudo-randomly scrambled by using a seed unique to the user in order to create the password actually used.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: A guide extension catheter includes a proximal shaft, a distal shaft, and a plurality of perfusion openings. The distal shaft includes a jacket and a helical coil structure embedded in the jacket, the distal shaft defining a lumen. The plurality of perfusion openings are disposed though the jacket of the distal shaft between windings of the helical coil structure. The guide extension catheter provides additional back support to the guide catheter. The plurality of perfusion openings allow fluid communication between an area outside the guide extension catheter and the lumen.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: Systems and methods for stimulating neural tissue are disclosed. An array of optically emissive pixels is configured to deliver light to the neural tissue of a subject. Individual pixels within the array can be addressed to selectively illuminate a portion of the neural tissue when a neurological event occurs. The system can also include an array of microelectrodes in electrical communication with the array of pixels and a power source. A biocompatible substrate can be used to support the microelectrodes pixels, and the power source. A microelectrode circuit and a pixel circuit can also be supported by the biocompatible substrate.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: A processing system received data from a Fractional Flow Reserve device and communicates data to a conventional hemodynamic monitoring system having pressure displays. The processing system receives proximal pressure measurement signal from an aortic pressure measurement device and a distal pressure measurement signal from a distal pressure measurement device. A processor computes an FFR ratio from the proximal pressure measurement signal and the distal pressure measurement signal, and converts FFR ratio to a pressure format such that the FFR ratio reads on the conventional hemodynamic monitoring system as a pressure in units of pressure. The processing system transmits the proximal pressure measurement signal, the distal pressure measurement signal, and the FFR ratio in pressure format to the conventional hemodynamic monitoring system.

Abstract: A selectively attachable and removable visual and tactile assessment tool or clip for use with a mobile device is provided. Clip is an elongate member forming a curvilinear shape having a magnifying lens at a distal end thereof. Clip has a transparent tubular member disposed between first and second openings through the body portion of the clip. Tubular member has varying internal diameters to simulate, for example, the constriction or stenosis of a patient's vessel lumen. Once clip is attached to mobile device and the magnifying lens is positioned over the camera of the mobile device, a catheter is inserted through tubular member. The magnifying lens enlarges the size of the catheter displayed on the screen of the mobile device.

Abstract: The disclosed technology generally relates photovoltaic devices, and more particularly to methods of fabricating heterojunction interdigitated back contact photovoltaic cells having interdigitated emitter regions and back surface field regions.

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.

Abstract: Delivery systems for delivering medical devices and prosthetic heart valves in a patient's body are disclosed. The delivery system may include a catheter-based delivery system. The delivery system may include a tip, a capsule, an inner sheath, and a projection. The delivery system may include an outer sheath and a handle. The delivery system may be configured to be actuated via an actuator disposed on the handle. The projection may include an arm portion and a feeler portion. The feeler portion may include an indentation. The delivery system may be configured to correctly position a medical device or prosthetic heart valve.